Browse by Journal Title

2017

In vitro and in vivo investigations into the carbene gold chloride and thioglucoside anticancer drug candidates NHC-AuCl and NHC-AuSR.
Walther, W., Dada, O., O’Beirne, C., Ott, I., Sanchez-Sanz, G., Schmidt, C., Werner, C., Zhu, X. and Tacke, M.
Letters in Drug Design & Discovery 14 (2): 125-134. 2017

2014

In vitro and in vivo investigations into the carbene copper bromide anticancer drug candidate WBC4.
Walther, W., Fichtner, I., Hackenberg, F., Streciwilk, W. and Tacke, M.
Letters in Drug Design & Discovery 11 (7): 825-832. August 2014

2013

The activity of titanocene T against xenografted Caki-1 tumors.
Walther, W., Fichtner, I., Deally, A., Hogan, M. and Tacke, M.
Letters in Drug Design & Discovery 10 (5): 375-381. June 2013

2012

In vitro and in vivo investigations into the carbene silver acetate anticancer drug candidate SBC1.
Fichtner, I., Cinatl, J., Michaelis, M., Sanders, L.C., Hilger, R., Kennedy, B.N., Reynolds, A.L., Hackenberg, F., Lally, G., Quinn, S.J., McRae, I. and Tacke, M.
Letters in Drug Design & Discovery 9 (9): 815-822. November 2012

2011

The antiangiogenic and antitumoral activity of titanocene Y* in vivo.
Fichtner, I., Behrens, D., Claffey, J., Deally, A., Gleeson, B., Patil, S., Weber, H. and Tacke, M.
Letters in Drug Design & Discovery 8 (4): 302-307. May 2011

2008

Antitumor activity of oxali-titanocene Y in xenografted CAKI-1 tumors in mice.
Fichtner, I., Behrens, D., Claffey, J., Gleeson, B., Hogan, M., Wallis, D., Weber, H. and Tacke, M.
Letters in Drug Design & Discovery 5 (8): 489-493. December 2008

Antitumor activity of Titanocene Y in xenografted PC3 tumors in mice.
Dowling, C.M., Claffey, J., Cuffe, S., Fichtner, I., Pampillon, C., Sweeney, N.J., Strohfeldt, K., Watson, R.W. and Tacke, M.
Letters in Drug Design & Discovery 5 (2): 141-144. March 2008